Sanchez-Bilbao et al. IV vs SC tocilizumab in 471 GCA patients. No differences in sustained remission or glucocorticoid-sparing. Numerically more AEs in IV but this due to longer follow up, no difference when corrected @rheumnow #ACR22 Abstr#0146
Intravenous versus Subcutaneous Tocilizumab in a Series of 471 Patients with Giant Cell Arteritis - ACR Meeting Abstracts
